We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Alfasigma has entered into an exclusive licensing agreement with PhaseBio Pharmaceuticals, Inc., for the commercialization of bentracimab in 49 countries across Europe and other key markets.
Venous-lymphatic World International Network foundation (v-WIN), a no profit global organization dedicated to research and education in the venous & lymphatic field has developed a public and health professional awareness not-for-profit project called ...